Which of the following is NOT considered an aspect of Good Clinical Practice (GCP)?

The correct choice is that fast-tracking drug approvals is not considered an aspect of Good Clinical Practice (GCP). GCP refers to the ethical and scientific quality standards for designing, conducting, recording, and reporting clinical trials that involve human subjects. Its primary focus is on ensuring the protection of trial subjects' rights, safety, and well-being, as well as the credibility of the data collected.

The design of clinical trials is a core component of GCP, as it lays the groundwork for how the study will be conducted and ensures that the research questions are valid and ethical. Conducting clinical audits is also relevant under GCP, as audits are performed to verify compliance with protocols and regulations ensuring the integrity of the trial data. Furthermore, the protection of trial subjects' rights is a fundamental principle of GCP, emphasizing informed consent and the welfare of participants.

In contrast, fast-tracking drug approvals pertains more to regulatory processes and mechanisms that different health authorities may use to expedite the review of drugs under certain circumstances. While fast-tracking aims to hasten patient access to potentially life-saving medications, it does not fall under the GCP framework that governs the ethical conduct and quality of clinical trials.